Precision Neuroscience Corporation, a brain-computer interface technology company, announced on September 24, 2026, that it closed an oversubscribed $250 million Series D financing round. The round was co-led by Pershing Square Inc., the Ackman Oxman Institute, and an undisclosed leading life sciences investment fund, with participation from additional institutional and family office investors. The financing brings Precision's total funding since its 2021 founding to $430 million and strengthens its position in the emerging BCI sector.
Investor Confidence and Market Position
The breadth of the financing group spans sovereign wealth funds, venture capital firms, public-market investors, and prominent family offices, reflecting growing conviction that BCI is a consequential healthcare and technology category. Participants include the Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners, Hitachi Ventures, and JSL Health Capital. The round solidifies Precision's leadership at a time when the company has built the largest clinical footprint in BCI.
Clinical Milestones and Technology Validation
Precision has completed more than 100 patient procedures across 18 major medical institutions, establishing the largest clinical network in the BCI field. Its partners include the Perelman School of Medicine at the University of Pennsylvania, the University of Chicago Medicine, the Mount Sinai Health System, and West Virginia University's Rockefeller Neuroscience Institute. The company has also received FDA clearance for its Layer 7 cortical interface and demonstrated high-resolution neural recording across 4,096 electrodes with real-time decoding of intended movement.
Manufacturing and Commercial Partnerships
Precision maintains end-to-end control of its electrode arrays through a wholly owned MEMS manufacturing facility in Texas, supporting quality and scalability. The company has formed an industry-first partnership with Medtronic to integrate its technology with an established neurosurgical platform. This manufacturing base and commercial relationship are central to Precision's ability to move its cortical interface toward broader clinical use.
Research Recognition and Scientific Leadership
Peer-reviewed research has validated the performance of the Layer 7 cortical interface, including a study published in Nature Biomedical Engineering and clinical work with Johns Hopkins University. A University of Pennsylvania study used high-resolution recordings from Layer 7 to produce a refined map of the human motor cortex. The company also added Dr. John Donoghue, founder of BrainGate and a 2026 Queen Elizabeth Prize for Engineering laureate, as a scientific advisor.
Funding to Advance Clinical and Commercial Goals
Precision will use the Series D financing to expand its clinical program, advance Layer 7 through the next stages of FDA review, and build the infrastructure needed for commercialization. The investment follows a period of milestones across clinical care, regulatory progress, research, and manufacturing. These advances have positioned the company to scale its technology for patients living with neurological injuries.
Executive Perspectives
Michael Mager, Precision's co-founder and CEO, said the next phase of BCI will be defined by more than technology alone, emphasizing the company's clinical network, regulatory position, and manufacturing base. Bill Ackman, CEO of Pershing Square and co-founder of the Ackman Oxman Institute, said neurotechnology will be central to the next generation of cures, treatments, and rehabilitation. He added that Precision has the team, technology, and ambition to become an industry leader.
With $250 million in new capital and a broad investor syndicate, Precision Neuroscience is positioned to deepen its clinical footprint and pursue commercialization of its Layer 7 cortical interface. The company's progress across patient procedures, regulatory clearance, research, and manufacturing indicates a maturing BCI ecosystem with clear momentum. As it advances through FDA review and expands its partner network, Precision is likely to play a central role in shaping how neurotechnology is used in patient care.